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growth of human hepatoma cell lines in vitro
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Summary The effects of various chemotherapeutic agents on alpha-fetoprotein (AFP) secretion and growth
of human hepatocellular carcinoma and hepatoblastoma cell lines were investigated in vitro. It was found that
there was a high correlation between hepatoma cell number and AFP secretion after treatment and that the
amount of AFP secreted per cell per 72h was not affected with therapeutically achievable concentrations.
These results suggest that serum AFP level in patients with hepatomas does not correlate with the size of
whole tumour but with that of viable tumour mass, and that AFP-secreting capacity of tumour cells in the
mass is kept unchanged after chemotherapy.
Serum level of alpha-fetoprotein (AFP) is often increased in
patients with hepatocellular carcinoma (HCC) or hepatoblas-
toma, and therefore the expression of AFP has served
as a reliable tumour marker for diagnosis or therapy of
HCC or hepatoblastoma. Many studies have been concerned
with the correlation between AFP levels and tumour mass in
patients (Johnson & Williams, 1980; Pritchard et al., 1982)
or animals (Lo et al., 1973; Tsukada et al., 1974; Sell et al.,
1974) with hepatoma. The relationship of serum AFP con-
centration to tumour mass was examined using human
hepatocellular carcinoma cell line PLC/PRF/5-bearing nude
mice, for the purpose of validating the use of changes in
serum AFP level as a means of following response to
therapy, and it was concluded that there was a positive
correlation between serum AFP level and total tumour
burden (Bassendine et al., 1983). However, it seemed to be
difficult to estimate whether or not the AFP-producing
capacity of hepatoma cells was affected by treatment with
chemotherapeutic agents from their whole tumour study.
We examined in this study the change of secretion of AFP
and that of cell number by treatment of human hepatocellu-
lar carcinoma and hepatoblastoma cells with various che-
motherapeutic agents in vitro.
Materials and methods
Cell lines
Human well-differentiated hepatocellular carcinoma (HuH-7)
(Nakabayashi et al., 1982) and well-differentiated hepato-
blastoma (HuH-6) (Doi, 1976) cell lines were used. The
population doubling times of HuH-7 and HuH-6 were 46.3 h
and 83.1 h, respectively. The culture media used were RPMI-
1640 (Nissui-Seiyaku, Japan) supplemented with 0.2% lact-
albumin hydrolysate (Difco) and 2% bovine serum (BS) with
60pgml-1 of kanamycin sulphate (Meiji-Seika, Japan). All
dishes were kept at 37°C in a humidified atmosphere of 5%
CO2 and 95% air.
Chemotherapeutic agents
Mitomycin C (MMC), Adriamycin (ADM), 5-fluorouracil
(5-FU) (Kyowa-Hakko, Japan) and cisplatinum (CDDP)
(Nihon-Kayaku, Japan), which have been commonly used
for the clinical treatment of hepatomas, were used as test
agents. All agents were diluted to final concentration in the
fresh medium and were used immediately for the experiment.
Cultured cells were treated with chemotherapeutic agents to
at least four concentrations including the therapeutically
achievable range, which is one-tenth the peak plasma con-
centration in human pharmacokinetics studies (3 x 10-7 M
for MMC, 7xlF-8M for ADM, 6x10-7M for CDDP and
5 x O-I M for 5-FU) (Von Hoff et al., 1981).
Cell growth and AFP determination
Cells were inoculated into 24 multi-well cluster dishes
(Falcon) coated with type I collagen (20pgml-1) (Nitta
gelatin, Japan) at densities of 5 x 104 cells per well (HuH-7)
or 8 x 1O4 cells per well (HuH-6). Three days after plating,
they were treated with chemotherapeutic agents for 30 min
at 37°C, and then rinsed with PBS. The culture media were
renewed every 3 days. Three and 6 days after treatment the
cells were dispersed into single cell suspensions with 0.2%
trypsin containing 0.02% EDTA and cell numbers were
counted with the aid of a Coulter counter. Study was
performed in triplicate. The spent media obtained from
HuH-6 and HuH-7 were centrifuged (3000g, 10min) and the
amount of AFP in the supernatant was determined by
enzyme-linked immunosorbent assay (ELISA) using rabbit
antihuman AFP and horse radish peroxidase-conjugated
rabbit antihuman AFP antibodies (Dako) (Tokiwa et al.,
1988). The limits of detection in ELISA were 1.Ong per tube.
The growth medium had no detectable AFP.
Statistics
Statistical analyses were performed using Student's t test.
Results
AFP secretion and cell growth
Figures 1 (HuH-7) and 2 (HuH-6) show the amounts of
AFP secreted per well per 72h and growth of cells treated
with chemotherapeutic agents. The level of AFP secreted by
HuH-7 was about twice that secreted by HuH-6. All the
agents used inhibited dose-dependently not only cell growth
but also the secretion of AFP. HuH-6 was generally more
resistant to the 4 agents used than HuH-7. Figures 3 and 4
represent the correlation between growth inhibition and AFP
secretion per well per 72h. Most data points for HuH-6 were
clustered towards control values. The correlation coefficient
(r) of HuH-7, which was calculated from the data on day 3,
day 6 and whole data after treatment, was 0.87 (P<0.01),
0.92 (P<0.01) and 0.91 (P<0.01), respectively. The correla-
tion coefficient (r) of HuH-6 was 0.85 (P<0.01), 0.86
(P<0.01) and 0.88 (P<0.01), respectively. No significant
difference was found between correlation coefficient of day 3
and that of day 6 in the two cell lines. Concerning the
difference of chemotherapeutic agents, the correlation coeffi-
cient of HuH-7 treated with MMC, ADM, CDDP and 5-FU
was 0.89 (P<0.01), 0.83 (P<0.01), 0.85 (P<0.01) and 0.59
Correspondence: A. Muraoka.
Received 30 September 1988, and in revised form, 13 December
1988.
Br. J. Cancer (1989), 59, 569-572570 A. MURAOKA et al.
(P<0.05), respectively, and that of HuH-6 was 0.51 (not
significant), 0.82 (P<0.01), 0.84 (P<0.01) and 0.84
(P<0.01), respectively.
The higher correlation was found in the case of ADM and
CDDP in both HuH-7 and HuH-6. As shown in Tables I
and II, the amount of AFP per 104 cells per 72h was little
affected, with only one exception (10-7 M MMC on HuH-6),
by treatment of cells with therapeutically achievable concen-
trations of agents. On the other hand, the amount of AFP
per 104 cells per 72h was reduced or increased by treatment
of cells with ADM at above 10-6M, with MMC at above
10-5M or with CDDP at above 10-4M.
105
Table I The amount of AFP 104 cells-1 72h-1 after treatment of
HuH-7
ng AFP secreted
104 cells-' 72h1-
Agent
MMC
ADM
CDDP
5-FU
Concentration
(logM)
Control
-8
-7
-6
-5
Control
-8
-7
-6
-5
Control
-7
-6
-5
-4
Control
-7
-6
-5
-4
-3
Day 3
after
treatment
507+44
600+ 55
540+40
569+102
600+133
538 + 64
817+211
648+ 59
716+81
543+ 170
392+28
400+37
396+ 72
470+37
264+68a
435 + 133
393+31
513 +35
639+54
618+ 150
473 + 54
Day 6
after
treatment
582 +72
563 + 61
601+ 55
719+ 36
812+96a
866+ 136
649+64
988± 228
860+272
387+24a
648 +97
578 + 15
869+ 159
908+98a
426+68a
571+102
579+21
620+77
609+ 118
430+91
418 +33
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Figure 1 Growth and AFP secretion of HuH-7. Continuous
lines and broken lines represent cell growth and AFP secretion,
respectively. 0, control; A, 10-8M; C1, 10-7M; 0, 10-6M; A,
10 5rM; *, 10-4M; V, 10-3M.
Data represent the mean+s.d. (n=3-6).
aSignificantly different from control (P<0.01).
Table II The amount of AFP 104 cells-1 72h-1 after treatment of
HuH-6
ng AFP secreted
104 cells-' 72h-1
Day 3 Day 6
Concentration after after
Agent (logM) treatment treatment
MMC Control 234+29 313+43
ADM
CDDP
-8
-7
-6
-5
Control
-8
-7
-6
-5
Control
-7
-6
-5
-4
216+20
165+7a
194+37
282+6
142+6
132+13
129+ 12
154+7
255+21a
191+27
190± 32
177+31
187+22
376+30a
..J IY T- tJ
344+ 12
244+3
268+41
463+25ka
237+ 37
171 +20
170+14
243+22
784+ 146a
329+ 39
326+1
260+14
237+ Ila
1051 +98a
5-FU Control 198+20 227+36
-7 202+16 219+22
-6 181+16 212+8
-5 184+4 193+3
-4 181+10 181+12
-3 158+8 170+20
Data represent the mean+s.d. (n=3-6). 0Significantly different from control (P<0.01).
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Figure 2 Growth and AFP secretion of HuH-6. Continuous
lines and broken lines represent cell growth and AFP secretion,
respectively. *, control; A, 10-8M; E], 10-7M; 0, 10-6M; A, 10-5M; U, 10-4M; V, 10-3M.
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Figure 3 Correlation between growth inhibition (% control) and
AFP secretion 72h-1 well-' (% control) of HuH-7, (0) 3 days
and (A) 6 days after treatment. Regression line was
y= 1.09x+0.81, and correlation coefficient (r) was 0.91 (P<0.01)
(see Results).
Discussion
AFP has been a useful tool for diagnosis and indicator after
treatment such as surgical operation, chemotherapy, trans-
catheter arterial embolization (TAE), hyperthermia and so
on (Matsumoto et al., 1974; McIntire et al., 1976; Johnson et
al., 1978). There are some early reports including studies on
choriocarcinomas that serum or tumour AFP level does not
correlate with tumour mass (Purves et al., 1970; Masseyeff,
1978; Raghavan et al., 1980). On the other hand, positive
correlations between them have also been demonstrated by
patient studies (Johnson & Williams, 1980) or model systems
where mice transplanted with a human hepatocellular carci-
noma cell line PLC/PRF/5 were used (Bassendine et al.,
1983; Curtin et al., 1986). In the latter study, however, it
seemed to be difficult to obtain reliable estimates of viable
tumour mass and the amount of AFP secreted per cell
because of the inclusion of many necrotic portions, especially
after treatment. Thus, highly AFP-producing human hepa-
toma cell lines seem to be a suitable model for investigation
of the growth capacity of cells or the amount of AFP
secreted per cell. Few cell lines, however, have been available
for such studies so far. The present studies were carried out
using two human hepatocellular carcinoma and hepatoblas-
toma cell lines which were established in our laboratory and
retained high AFP-producing capacity even in culture. These
results show: (a) that there is a high correlation between
tumour cell number and AFP secretion after treatment in
vitro, corresponding to the data that were obtained by the
patient studies or model systems described above; and (b)
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Figure 4 Correlation between growth inhibition (% control) and
AFP secretion 72h- well-' (% control) of HuH-6, (0) 3 days
and (-) 6 days after treatment. Regression line was
y=0.73 x+ 13.08, and correlation coefficient (r) was 0.88
(P<0.01) (see Results).
that the amount of AFP secreted per cell was not affected,
with only one exception, by the treatment of cells with
therapeutically achievable concentrations of chemothera-
peutic agents, but affected with higher concentrations of
some agents. These data suggest that serum AFP level in
patients correlates with the size of viable tumour mass rather
than that of whole tumour, and that AFP-secreting capacity
of tumour cells in the tumour mass is kept unchanged after
chemotherapy. Chemotherapeutic agents at above 10-4 M
seem to be toxic to the cells. In fact, many non-viable or
morphological impaired cells were observed at these concen-
trations (data not shown). It seems likely that the data at
higher concentration do not reflect exactly the AFP-secreting
capacity of cells.
Not only therapeutically achievable concentration, but
also area under the concentration curve (AUC) are impor-
tant as pharmacokinetic parameters of drug behaviour
(Salmon, 1984; Slee et al., 1986). The AUC is defined as the
product of concentration and exposure time. It was found
that the concentrations used in the present study were still
valid by using these AUCs.
Despite the development of diagnosis, world-wide primary
hepatomas have been one of the most lethal diseases (Liver
Cancer Study Group of Japan, 1984; Dunk et al., 1988), and
the exploitation of new effective chemotherapeutic agents has
been needed. In vitro culture systems using highly AFP-
producing hepatoma cell lines may provide a new drug
screening model for hepatomas.
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